Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
Want to see IN:LAURUSLABS full AI Analyst Report?
Top Page
Laurus Labs Ltd.
(LAURUSLABS)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹1,519.00
▲(37.21% Upside)
Action:Reiterated
Date:06/06/26
The score is driven primarily by improving profitability and a healthier leverage trend, but is held back by weak/volatile free cash flow and a very high valuation multiple. Technically, the trend is strong, yet overbought indicators increase near-term pullback risk.
Positive Factors
Diversified business model
Laurus operates across APIs, finished formulations and CDMO services, supplying regulated and emerging markets. This multi-pronged model spreads revenue sources, leverages manufacturing/R&D capabilities, and creates durable customer relationships and switching costs over the medium term.
Negative Factors
Weak free cash flow
Persistent weak or negative free cash flow, and a steep FCF decline, signal heavy capex or working-capital absorption that constrains internal funding. Low FCF relative to earnings limits buyback/dividend capacity and makes the business more reliant on external financing for growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Laurus operates across APIs, finished formulations and CDMO services, supplying regulated and emerging markets. This multi-pronged model spreads revenue sources, leverages manufacturing/R&D capabilities, and creates durable customer relationships and switching costs over the medium term.
Read all positive factors
Laurus Labs Ltd. (LAURUSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹752.61B
Dividend Yield0.15%
Average Volume (3M)107.31K
Price to Earnings (P/E)84.4
Beta (1Y)0.93
Revenue Growth22.67%
EPS Growth147.77%
CountryIN
Employees6,007
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.68
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,130.00Price Target Upside2.07% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)20.77
Revenue Forecast (FY)₹78.92B
Laurus Labs Ltd. Business Overview & Revenue Model
Company Description
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a br...
How the Company Makes Money
Laurus Labs makes money primarily by manufacturing and selling pharmaceutical products and related services. Key revenue streams include: (1) Sale of APIs: Laurus produces and supplies active pharmaceutical ingredients to other drug manufacturers;...
Laurus Labs Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
72
Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.58B | 68.13B | 55.54B | 50.41B | 60.41B | 49.36B |
| Gross Profit | 32.18B | 27.42B | 29.65B | 25.01B | 31.81B | 26.87B |
| EBITDA | 14.81B | 18.33B | 10.34B | 7.63B | 16.06B | 14.18B |
| Net Income | 6.84B | 8.89B | 3.58B | 1.61B | 7.90B | 8.28B |
Balance Sheet | ||||||
| Total Assets | 94.15B | 105.11B | 93.36B | 83.87B | 76.60B | 69.68B |
| Cash, Cash Equivalents and Short-Term Investments | 633.80M | 1.14B | 1.44B | 1.42B | 484.60M | 759.40M |
| Total Debt | 22.12B | 25.18B | 27.64B | 25.77B | 20.15B | 17.77B |
| Total Liabilities | 44.82B | 50.80B | 47.33B | 42.71B | 36.12B | 36.09B |
| Stockholders Equity | 48.05B | 53.00B | 44.73B | 41.11B | 40.38B | 33.51B |
Cash Flow | ||||||
| Free Cash Flow | 6.04B | 3.89B | -393.50M | -126.20M | 37.40M | 342.60M |
| Operating Cash Flow | 10.93B | 14.59B | 6.02B | 6.66B | 9.94B | 9.11B |
| Investing Cash Flow | -4.77B | -10.95B | -6.82B | -8.22B | -9.96B | -9.14B |
| Financing Cash Flow | -6.68B | -3.54B | 392.80M | 2.50B | -266.40M | 302.60M |
Laurus Labs Ltd. Technical Analysis
Positive
1107.05
Price Trends
1230.76
Positive
1121.19
Positive
1039.63
Positive
Market Momentum
49.84
Positive
62.20
Neutral
29.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LAURUSLABS, the sentiment is Positive. The current price of 1107.05 is below the 20-day moving average (MA) of 1378.26, below the 50-day MA of 1230.76, and above the 200-day MA of 1039.63, indicating a bullish trend. The MACD of 49.84 indicates Positive momentum. The RSI at 62.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LAURUSLABS.
Laurus Labs Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹4.34T | 37.79 | ― | 0.91% | 11.19% | 5.01% | |
75 Outperform | ₹1.76T | 68.27 | ― | 0.46% | 12.82% | 17.23% | |
73 Outperform | ₹1.05T | 19.48 | ― | 0.57% | 23.12% | 62.27% | |
68 Neutral | ₹855.09B | 23.34 | ― | 0.33% | 6.08% | 0.77% | |
67 Neutral | ₹1.06T | 24.90 | ― | 0.63% | 3.19% | -24.30% | |
60 Neutral | ₹752.61B | 84.39 | ― | 0.15% | 22.67% | 147.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LAURUSLABS
Laurus Labs Ltd.
1,389.30
710.64
104.71%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,407.00
267.38
23.46%
IN:DIVISLAB
Divi's Laboratories Limited
6,608.15
-50.53
-0.76%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,279.25
-59.01
-4.41%
IN:LUPIN
Lupin Limited
2,273.50
275.36
13.78%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,806.45
137.28
8.22%
Laurus Labs Ltd. Corporate Events
Laurus Labs Closes Trading Window Ahead of FY26 Results
Mar 30, 2026
Laurus Labs Limited has announced that its trading window for dealing in the company’s securities will be closed from April 1, 2026, until 48 hours after the declaration of its audited financial results for the quarter and year ended March 3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.